A second case of sunitinib-associated pyoderma gangrenosum

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 8, 2010, Pages 34-35

  Dean, Steven M ^a   Zirwas, Matthew ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MINOCYCLINE; SUNITINIB;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CELL INFILTRATION; COMPRESSION THERAPY; DEBRIDEMENT; DRUG WITHDRAWAL; EDEMA; FEMALE; GASTROCNEMIUS MUSCLE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; NEPHRECTOMY; NEUTROPHIL; PUSTULE; PYODERMA GANGRENOSUM; RECURRENT CANCER; SKIN BIOPSY; SKIN ULCER; SUPPURATION; TISSUE CULTURE;

EID: 77957683079     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Gungor K, Gonen S, Kisakol G, et al. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest. 2006;29:575-576.
2. White LE, Villa MT, Petronic-Rosic V, et al. Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed. 2006;5:96-98.
3. Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer. 1991;15(68):441-443.
4. Montoto S, Bosch F, Estrach T, et al. Pyoderma gangrenosum triggered by alpha 2b-interferon in a patient with chronic granulocytic leukemia. Leuk Lymphoma. 1998;30:199-202.
5. Sanders S, Busam K, Tahan SR, et al. Granulomatous and suppurative dermatitis at interferon alpha injection sites: report of two cases. J Am Acad Dermatol. 2002;46:611-616.
6. Sagara R, Kitami A, Nakada T, et al. Adverse reactions to gefitinib [Iressa ®]: revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol. 2006;45:1002.
7. Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159:242-243.
8. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009 May 5. [Epub ahead of print].
9. Morita E, Lee DG, Sugiyama M, et al. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res. 1994;286:273-277.
10. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelia cell survival mechanisms. FASEB J. 2004;18:338-340.
11. Ayirookuzhi SJ, Ma L, Ramshesh P, et al. Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005;141:368-370.
12. Schwarz M, Kreuzer KA, Baskaynak G, et al. Imatinib-induced acute generalized exanthematous pustulosis [AGEP] in two patients with chronic myeloid leukemia. Eur J Haematol. 2002;69:254-256.